Back to top
more

Dr. Reddys Laboratories (RDY)

(Delayed Data from NYSE)

$70.84 USD

70.84
299,089

-0.86 (-1.20%)

Updated Jun 18, 2024 04:00 PM ET

After-Market: $70.81 -0.03 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 249)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen

Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.

The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power

The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power

BridgeBio Pharma (BBIO) Jumps: Stock Rises 7.1%

BridgeBio Pharma (BBIO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Foamix Initiates Phase II Study on Acne Combination Foam

Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

Tirthankar Chakraborty headshot

Is it Apt to Foray Into the Indian Stock Market?: An Analysis

The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%.

J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use

J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.

Zynerba Releases Data on Epilepsy Candidate, Stock Down

Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.

Top Ranked Momentum Stocks to Buy for September 17th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 17th

What Makes Doctor Reddy's (RDY) a Strong Momentum Stock: Buy Now?

Does Doctor Reddy's (RDY) have what it takes to be a top stock pick for momentum investors? Let's find out.

The Zacks Analyst Blog Highlights: Apple, Harmony Gold, NRG, Ryman Hospitality and Dr. Reddy's

The Zacks Analyst Blog Highlights: Apple, Harmony Gold, NRG, Ryman Hospitality and Dr. Reddy's

Sweta Killa headshot

Top Stories of August Worth Watching in September

We discuss some of the events that dominated the headlines in August and will be worth watching this month.

5 Stocks From the Best Performing Sectors in Q2

We have shortlisted solid stocks from the top-performing sectors in Q2 that should make a great addition to your portfolio.

Sweta Killa headshot

5 Stock-Picking Strategies to Counter Market Turbulence

We have highlighted some stock-picking ideas from the top-ranked cohort that could prove extremely beneficial for investors by reducing the risk of a downside.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for August 1st

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y

Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.

Dr. Reddy's Inks Deal to Sell Neurology Branded Products

Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.

Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug

Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.

BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady

BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.

New Strong Sell Stocks for May 22nd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates

Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.

Dr. Reddy's (RDY) Earnings Rise in Q4, Revenues Beat

Dr. Reddy's earnings and sales increase year over year in the fourth quarter of fiscal 2019.

Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?

Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.

Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs

Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.

Supernus' ADHD Candidate Positive in 4th Phase III Study

Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.

Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)

Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.